摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(benzo[c][1,2,5]thiadiazol-5-ylamino)-4-(cyclopropylamino)pyrimidine-5-carboxamide | 1198302-92-9

中文名称
——
中文别名
——
英文名称
2-(benzo[c][1,2,5]thiadiazol-5-ylamino)-4-(cyclopropylamino)pyrimidine-5-carboxamide
英文别名
US9868729, Example 325;2-(2,1,3-benzothiadiazol-5-ylamino)-4-(cyclopropylamino)pyrimidine-5-carboxamide
2-(benzo[c][1,2,5]thiadiazol-5-ylamino)-4-(cyclopropylamino)pyrimidine-5-carboxamide化学式
CAS
1198302-92-9
化学式
C14H13N7OS
mdl
——
分子量
327.37
InChiKey
OMQTXRAOVUDBME-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    147
  • 氢给体数:
    3
  • 氢受体数:
    8

文献信息

  • [EN] 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS<br/>[FR] 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
    申请人:PORTOLA PHARM INC
    公开号:WO2009145856A1
    公开(公告)日:2009-12-03
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
    本发明涉及式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体,这些化合物是syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体,制备这种化合物,含有这种化合物的药物组合物,抑制syk和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗由syk和/或JAK激酶活性至少部分介导的多种疾病的方法,如心血管疾病、炎症性疾病、自身免疫疾病和细胞增殖障碍、血栓形成、过敏、哮喘、类风湿关节炎、白血病或非霍奇淋巴瘤。
  • Inhibitors of protein kinases
    申请人:Bauer Shawn M.
    公开号:US20090318407A1
    公开(公告)日:2009-12-24
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    本发明涉及式I-II化合物及其药学上可接受的互变异构体、盐或立体异构体,其是SYK和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体,该化合物的制备,含有该化合物的制药组合物,抑制SYK和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗由SYK和/或JAK激酶活性至少部分介导的多种疾病,如不良血栓和非霍奇淋巴瘤的方法。
  • INHIBITORS OF PROTEIN KINASES
    申请人:Bauer Shawn M.
    公开号:US20120129867A1
    公开(公告)日:2012-05-24
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    本发明涉及式I-II化合物及其药学上可接受的互变异构体、盐或立体异构体,其为syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体,制备这种化合物的方法,包含这种化合物的制药组合物,抑制syk和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗至少部分由syk和/或JAK激酶活性介导的多种情况的方法,例如不良血栓形成和非何杰淋巴瘤。
  • 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS
    申请人:Portola Pharmaceuticals, Inc.
    公开号:EP2321283A1
    公开(公告)日:2011-05-18
  • US8138339B2
    申请人:——
    公开号:US8138339B2
    公开(公告)日:2012-03-20
查看更多

同类化合物

(5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 阿拉酸式苯-S-甲基 阿拉酸式苯 试剂4,7-Bis(5-bromo-2-thienyl)-5,6-bis(dodecyloxy)-2,1,3-benzothiadiazole 苯并恶唑-6-胺 苯并[d][1,2,3]噻二唑-6-羧酸 苯并[C][1,2,5]噻二唑-5-硼酸频那醇酯 苯并[C][1,2,5]噻二唑-4-磺酸钠 苯并[C][1,2,5]噻二唑-4-基甲醇 苯并[C][1,2,5]噻二唑-4,7-二甲醛 苯并[C][1,2,5]噻二唑-4,7-二基二硼酸 苯并[1,2,5]噻二唑-4-羧酸 苯并[1,2,5]噻二唑-4-磺酰氯 苯并[1,2,3]噻二唑-7-基胺 苯并[1,2,3]噻二唑-6-羧酸甲酯 苯并[1,2,3]噻二唑-5-基胺 苯并[1,2,3]噻二唑-4-基胺 苯2,1,3-噻重氮-5-羧酸酯 碘化(2,1,3-苯并硫杂(SIV)二唑-5-基)二甲基八氧代甲基铵 硫代磷酸S-[(2,1,3-苯并噻二唑-5-基)甲基]酯O,O-二钠盐 盐酸替扎尼定-d4 盐酸替扎尼定 灭草荒 替托尼定D4 替扎尼定杂质1 替扎尼定EP杂质C 替扎尼定 噻唑并[4,5-f]-2,1,3-苯并噻二唑,6-甲基-(6CI,8CI) 去氢替扎尼定 全氟苯并[c][1,2,5]噻二唑 [7-[2-[2-(8-硫杂-7,9-二氮杂双环[4.3.0]壬-3,5,9-三烯-7-基)乙基二巯基]乙基]-8-硫杂-7,9-二氮杂双环[4.3.0]壬-3,5,9-三烯-2-基]甲胺 Y6醛 N-甲氧基-N-甲基-2,1,3-苯并噻二唑-5-酰胺 N-(5-氯-2,1,3-苯并噻二唑-4-基)硫脲 N,N'-二硫代二(亚乙基)二(2,1,3-苯并噻二唑-5-甲胺) N'-2,1,3-苯并噻二唑-4-基-N,N-二甲基酰亚胺基甲酰胺 EA671;;二噻吩[3,2-E:2,3-G]-2,1,3-苯并噻二唑 BTQBT(升华提纯) 7H-咪唑并[4,5-g][1,2,3]苯并噻二唑 7H-咪唑并[4,5-e][1,2,3]苯并噻二唑 7-肼基[1,3]噻唑并[5,4-e][2,1,3]苯并噻二唑 7-肼基[1,3]噻唑并[4,5-e][2,1,3]苯并噻二唑 7-碘-苯并[1,2,3]噻二唑 7-硝基-苯并[1,2,5]噻二唑-4-基胺 7-硝基-1,2,3-苯并噻二唑 7-甲基[1,3]噻唑并[5,4-e][2,1,3]苯并噻二唑 7-甲基[1,3]噻唑并[4,5-e][2,1,3]苯并噻二唑 7-甲基[1,3]噻唑并[4,5-e][1,2,3]苯并噻二唑 7-溴苯并[c][1,2,5]噻二唑-4-磺酸 7-溴-苯并[D][1,2,3]噻二唑